Advances in LC/MS/MS detection limits enable the use of stable isotopically labeled drug forms to accurately quantify bioavailability assays.
Download this poster to explore the methods, results, and conclusions of this study.
Complete the form below to access this scientific poster
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
